Catalyst Brief

← Calendar

Readoutin 45d

Hoffmann-La Roche — Afimkibart

Phase 3 primary completion: A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis.

Date
Jan 2027
Type
Readout
Indication
Moderately to Severely Active Ulcerative Colitis

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.

More from Hoffmann-La Roche

  1. Mar2027
    Readoutin 104d
    Hoffmann-La Roche — Atezolizumab
    Phase 3 primary completion: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy.
  2. Feb2027
    Readoutin 76d
    Hoffmann-La Roche — Ranibizumab
    Phase 3 primary completion: A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome).